Literature DB >> 24474780

Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.

P Patrizia Mangione1, Riccardo Porcari, Julian D Gillmore, Piero Pucci, Maria Monti, Mattia Porcari, Sofia Giorgetti, Loredana Marchese, Sara Raimondi, Louise C Serpell, Wenjie Chen, Annalisa Relini, Julien Marcoux, Innes R Clatworthy, Graham W Taylor, Glenys A Tennent, Carol V Robinson, Philip N Hawkins, Monica Stoppini, Stephen P Wood, Mark B Pepys, Vittorio Bellotti.   

Abstract

The Ser52Pro variant of transthyretin (TTR) produces aggressive, highly penetrant, autosomal-dominant systemic amyloidosis in persons heterozygous for the causative mutation. Together with a minor quantity of full-length wild-type and variant TTR, the main component of the ex vivo fibrils was the residue 49-127 fragment of the TTR variant, the portion of the TTR sequence that previously has been reported to be the principal constituent of type A, cardiac amyloid fibrils formed from wild-type TTR and other TTR variants [Bergstrom J, et al. (2005) J Pathol 206(2):224-232]. This specific truncation of Ser52Pro TTR was generated readily in vitro by limited proteolysis. In physiological conditions and under agitation the residue 49-127 proteolytic fragment rapidly and completely self-aggregates into typical amyloid fibrils. The remarkable susceptibility to such cleavage is likely caused by localized destabilization of the β-turn linking strands C and D caused by loss of the wild-type hydrogen-bonding network between the side chains of residues Ser52, Glu54, Ser50, and a water molecule, as revealed by the high-resolution crystallographic structure of Ser52Pro TTR. We thus provide a structural basis for the recently hypothesized, crucial pathogenic role of proteolytic cleavage in TTR amyloid fibrillogenesis. Binding of the natural ligands thyroxine or retinol-binding protein (RBP) by Ser52Pro variant TTR stabilizes the native tetrameric assembly, but neither protected the variant from proteolysis. However, binding of RBP, but not thyroxine, inhibited subsequent fibrillogenesis.

Entities:  

Keywords:  misfolding; protein aggregation

Mesh:

Substances:

Year:  2014        PMID: 24474780      PMCID: PMC3910611          DOI: 10.1073/pnas.1317488111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.

Authors:  X Jiang; C S Smith; H M Petrassi; P Hammarström; J T White; J C Sacchettini; J W Kelly
Journal:  Biochemistry       Date:  2001-09-25       Impact factor: 3.162

2.  Unfolding and aggregation of transthyretin by the truncation of 50 N-terminal amino acids.

Authors:  Mineyuki Mizuguchi; Ayumi Hayashi; Makoto Takeuchi; Mizuki Dobashi; Yoshihiro Mori; Hiroyuki Shinoda; Tomoyasu Aizawa; Makoto Demura; Keiichi Kawano
Journal:  Proteins       Date:  2008-07

3.  Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.

Authors:  Joakim Bergström; Asa Gustavsson; Ulf Hellman; Knut Sletten; Charles L Murphy; Deborah T Weiss; Alan Solomon; Bert-Ove Olofsson; Per Westermark
Journal:  J Pathol       Date:  2005-06       Impact factor: 7.996

Review 4.  The effects of shear flow on protein structure and function.

Authors:  Innocent B Bekard; Peter Asimakis; Joseph Bertolini; Dave E Dunstan
Journal:  Biopolymers       Date:  2011-05-04       Impact factor: 2.505

5.  Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.

Authors:  Sophie Valleix; Julian D Gillmore; Frank Bridoux; Palma P Mangione; Ahmet Dogan; Brigitte Nedelec; Mathieu Boimard; Guy Touchard; Jean-Michel Goujon; Corinne Lacombe; Pierre Lozeron; David Adams; Catherine Lacroix; Thierry Maisonobe; Violaine Planté-Bordeneuve; Julie A Vrana; Jason D Theis; Sofia Giorgetti; Riccardo Porcari; Stefano Ricagno; Martino Bolognesi; Monica Stoppini; Marc Delpech; Mark B Pepys; Philip N Hawkins; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2012-06-14       Impact factor: 91.245

6.  Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.

Authors:  A Gustavsson; H Jahr; R Tobiassen; D R Jacobson; K Sletten; P Westermark
Journal:  Lab Invest       Date:  1995-11       Impact factor: 5.662

7.  Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.

Authors:  Elisabet Ihse; Claudio Rapezzi; Giampaolo Merlini; Merrill D Benson; Yukio Ando; Ole B Suhr; Shu-Ichi Ikeda; Francesca Lavatelli; Laura Obici; Candida C Quarta; Ornella Leone; Hirofumi Jono; Mitsuharu Ueda; Massimiliano Lorenzini; Juris Liepnieks; Toshinori Ohshima; Masayoshi Tasaki; Taro Yamashita; Per Westermark
Journal:  Amyloid       Date:  2013-05-28       Impact factor: 7.141

8.  Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Authors:  Per Hammarström; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Science       Date:  2003-01-31       Impact factor: 47.728

9.  Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.

Authors:  P N Hawkins; J P Lavender; M B Pepys
Journal:  N Engl J Med       Date:  1990-08-23       Impact factor: 91.245

10.  Trapping of palindromic ligands within native transthyretin prevents amyloid formation.

Authors:  Simon E Kolstoe; Palma P Mangione; Vittorio Bellotti; Graham W Taylor; Glenys A Tennent; Stéphanie Deroo; Angus J Morrison; Alexander J A Cobb; Anthony Coyne; Margaret G McCammon; Timothy D Warner; Jane Mitchell; Raj Gill; Martin D Smith; Steven V Ley; Carol V Robinson; Stephen P Wood; Mark B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

View more
  36 in total

1.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

2.  Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils.

Authors:  Sara Raimondi; P Patrizia Mangione; Guglielmo Verona; Diana Canetti; Paola Nocerino; Loredana Marchese; Rebecca Piccarducci; Valentina Mondani; Giulia Faravelli; Graham W Taylor; Julian D Gillmore; Alessandra Corazza; Mark B Pepys; Sofia Giorgetti; Vittorio Bellotti
Journal:  J Biol Chem       Date:  2020-06-22       Impact factor: 5.157

3.  A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH.

Authors:  Mitsuharu Ueda; Masamitsu Okada; Mineyuki Mizuguchi; Barbara Kluve-Beckerman; Kyosuke Kanenawa; Aito Isoguchi; Yohei Misumi; Masayoshi Tasaki; Akihiko Ueda; Akinori Kanai; Ryoko Sasaki; Teruaki Masuda; Yasuteru Inoue; Toshiya Nomura; Satoru Shinriki; Tsuyoshi Shuto; Hirofumi Kai; Taro Yamashita; Hirotaka Matsui; Merrill D Benson; Yukio Ando
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

Review 4.  Noncerebral Amyloidoses: Aspects on Seeding, Cross-Seeding, and Transmission.

Authors:  Gunilla T Westermark; Marcus Fändrich; Katarzyna Lundmark; Per Westermark
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

5.  Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.

Authors:  Joseph D Schonhoft; Cecilia Monteiro; Lars Plate; Yvonne S Eisele; John M Kelly; Daniel Boland; Christopher G Parker; Benjamin F Cravatt; Sergio Teruya; Stephen Helmke; Mathew Maurer; John Berk; Yoshiki Sekijima; Marta Novais; Teresa Coelho; Evan T Powers; Jeffery W Kelly
Journal:  Sci Transl Med       Date:  2017-09-13       Impact factor: 17.956

Review 6.  Amyloidosis in Heart Failure.

Authors:  Sandra Ihne; Caroline Morbach; Laura Obici; Giovanni Palladini; Stefan Störk
Journal:  Curr Heart Fail Rep       Date:  2019-12

7.  Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses.

Authors:  Celia M Torres-Arancivia; Deborah Chang; William E Hackett; Joseph Zaia; Lawreen H Connors
Journal:  Biochemistry       Date:  2020-11-03       Impact factor: 3.162

Review 8.  Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.

Authors:  Jin-Beom Si; Bokyung Kim; Jin Hae Kim
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

9.  Disruption of the CD Loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway.

Authors:  Anvesh K R Dasari; Jenette Arreola; Brian Michael; Robert G Griffin; Jeffery W Kelly; Kwang Hun Lim
Journal:  Biochemistry       Date:  2020-06-14       Impact factor: 3.162

10.  Trypsin Induced Degradation of Amyloid Fibrils.

Authors:  Olga V Stepanenko; Maksim I Sulatsky; Ekaterina V Mikhailova; Olesya V Stepanenko; Irina M Kuznetsova; Konstantin K Turoverov; Anna I Sulatskaya
Journal:  Int J Mol Sci       Date:  2021-05-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.